Laboratorio de Resistencia Bacteriana, Instituto de Bacteriología y Virología Molecular (IBaViM), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.
Consejo Nacional de Investigaciones Científicas y Técnicas, Ciudad Autónoma de Buenos Aires, Argentina.
Front Cell Infect Microbiol. 2021 Apr 29;11:654852. doi: 10.3389/fcimb.2021.654852. eCollection 2021.
New Delhi metallo-β-lactamase (NDM)-producing isolates are usually resistant to most β-lactams and other antibiotics as a result of the coexistence of several resistance markers, and they cause a variety of infections associated to high mortality rates. Although NDM-1 is the most prevalent one, other variants are increasing their frequency worldwide. In this study we describe the first clinical isolate of NDM-5- and RmtB-producing in Latin America. (Ec265) was recovered from a urine sample of a female outpatient. Phenotypical and genotypical characterization of resistance markers and conjugation assays were performed. Genetic analysis of Ec265 was achieved by whole genome sequencing. Ec265 belonging to ST9693 (CC354), displayed resistance to most β-lactams (including carbapenems), aminoglycosides (gentamicin and amikacin), and quinolones. Several resistance genes were found, including and , located on a conjugative plasmid. genetic context is similar to others found around the world. Co-transfer of multiple antimicrobial resistance genes represents a particular challenge for treatment in clinical settings, whereas the spread of pathogens resistant to last resort antibiotics should raise an alarm in the healthcare system worldwide.
新德里金属β-内酰胺酶(NDM)产生的分离株通常由于存在几种耐药标记物而对大多数β-内酰胺类抗生素和其他抗生素具有耐药性,并且它们引起多种与高死亡率相关的感染。虽然 NDM-1 最为普遍,但其他变体在全球范围内的频率正在增加。在本研究中,我们描述了拉丁美洲首例 NDM-5 和 RmtB 产生的临床分离株。(Ec265)从一名女性门诊患者的尿液样本中分离得到。对耐药标记物的表型和基因型特征以及接合试验进行了研究。通过全基因组测序对 Ec265 的遗传分析。Ec265 属于 ST9693(CC354),对大多数β-内酰胺类抗生素(包括碳青霉烯类)、氨基糖苷类(庆大霉素和阿米卡星)和喹诺酮类药物均具有耐药性。发现了多个耐药基因,包括 和 ,位于一个可接合的质粒上。 基因结构与在世界各地发现的其他基因结构相似。多种抗菌药物耐药基因的共同转移对临床治疗构成了特殊挑战,而对最后手段抗生素耐药的病原体的传播应该在全球医疗保健系统中引起警报。